Skip to content
Review Open access

Progress toward poliomyelitis eradication — January 2023–December 2024

Aug 2026 · Archives of Public Health · 0 citations

TL;DR

The resurgence of WPV1 in polio-free regions in Afghanistan and Pakistan and the spread of cVDPVs challenge global polio eradication, highlighting the need for rapid detection, expanded nOPV2 use in areas with prolonged transmission, and sustained partner engagement and strategic resource allocation amid declining global health funding.

Abstract

Since the establishment of the Global Polio Eradication Initiative (GPEI) in 1988, wild poliovirus type 1 (WPV1) remains endemic in only Afghanistan and Pakistan. However, outbreaks of paralytic polio caused by circulating vaccine-derived polioviruses (cVDPVs) emerge in areas with low vaccination coverage and continue to challenge polio eradication goals. As the Global Polio Eradication Initiative extends its eradication target to 2029, understanding the epidemiologic, surveillance, and operational factors associated with persistent transmission is critical for informing policy decisions and targeting limited resources. This report describes global polio immunization efforts, surveillance activities, and epidemiology during January 2023–December 2024. Surveillance and virologic data were obtained from the World Health Organization’s (WHO) global Polio Information System (POLIS), and immunization coverage estimates were sourced from WHO’s Immunization Dashboard, which incorporates administrative and survey-based data from WHO and UNICEF. A cVDPV outbreak was defined using standardized acute flaccid paralysis (AFP) and environmental surveillance criteria; analyses were conducted in R (version 4.4.1). Afghanistan and Pakistan reported 99 WPV1 cases in 10 provinces in 2024, compared with 12 cases in 3 provinces in 2023. cVDPV cases decreased 12% from 529 in 2023 to 464 in 2024. However, cVDPV detections from AFP and environmental surveillance expanded geographically, with detections in 40 countries in Africa, Southeast Asia, the Middle East and Europe in 2024, including 14 countries with no detections in 2023. The resurgence of WPV1 in polio-free regions in Afghanistan and Pakistan and the spread of cVDPVs challenge global polio eradication. Achieving global polio eradication will require reaching persistently missed children in remote and insecure areas, strengthening vaccination and surveillance systems, and reinforcing accountability to improve campaign quality. The geographic expansion of cVDPV type 2 (cVDPV2) underscores the need for rapid detection, expanded nOPV2 use in areas with prolonged transmission, and sustained partner engagement and strategic resource allocation amid declining global health funding.

Read PDF

Similar papers

Review Open access Sep 2026

Poliomyelitis Eradication in Burkina Faso: Progress in Epidemiological Surveillance of Acute Flaccid Paralysis (AFP) and Environmental Surveillance from 2020 to 2024

Surveillance for acute flaccid paralysis (AFP) and environmental surveillance is one of the pillars of the polio eradication strategy, particularly in contexts marked by insecurity and the circulation of vaccine-derived polioviruses type 2 (cVDPV2). Through a descriptive and retrospective cross-sectional study, we eval...

Zongo Inoufou, Sawadogo Siméon, F. Kouéta et al. · 0 citations
Review Open access Sep 2026

The African Polio Laboratory Network: Advancing Regional Poliovirus Detection, Genomic Surveillance, and Eradication

Background: Sustaining progress toward polio eradication requires not only effective vaccination but also a resilient laboratory network capable of timely poliovirus detection, confirmation, and genetic characterization. In the WHO African region, the African polio laboratory network provides essential virological supp...

B. Tesfaye, T. Nomhwange, Shelina Moonsamy et al. · 0 citations
Open access Oct 2026

From eradicating wild poliovirus to eradicating vaccine-derived polioviruses: why oral polio vaccine use must now be ended.

Wild poliovirus (WPV)2 was eradicated globally in 1999, and WPV3 was eradicated in 2012. Since 2016, endemic transmission of WPV1 has remained restricted to Afghanistan and Pakistan. Circulating vaccine-derived polioviruses (cVDPVs) have become the leading cause of poliovirus transmission and paralytic disease globally...

D. Durrheim, R. Steinglass, Norbert Hirschhorn et al. · 0 citations
Review Open access Sep 2026

Progress towards measles and rubella elimination in Lesotho, 2011–2025

Background Lesotho, a lower middle-income country in southern Africa, has historically had relatively high routine immunization coverage over the last three decades. Since 1996, the country has been implementing measles elimination strategies. This manuscript evaluates Lesotho’s performance, from 2011 to 2025, against...

Yankuba Singhateh, Tshepiso Mechele Matoko, Mannini Shaabe et al. · 0 citations
Open access Aug 2026

Environmental Surveillance of Poliovirus in the Democratic Republic of the Congo: Sensitivity and Site Productivity, 2017–2025

Background: Environmental surveillance (ES) of wastewater was introduced by the Global Polio Eradication Initiative (GPEI) to improve the sensitivity of acute flaccid paralysis (AFP) surveillance. In the Democratic Republic of the Congo (DRC), ES for poliovirus has been implemented since 2017. This study assessed its s...

Vanessa Bakumba-Kiulu, Paul Tshiminyi-Munkamba, T. Kabeya-Mampuela et al. · 0 citations
Conference

Quantifying the Impact of Targeted Vaccine Distribution on Polio Outbreak Response Outcomes

Polio, a paralytic infectious disease, remains a pressing global health issue, particularly with the rise of circulating vaccine-derived poliovirus (cVDPV) and recurrent outbreaks in regions with under-immunized children. Prior research has indicated that prioritizing vaccination for under-immunized children during out...

Yu-Ming Sun, Hong-Yu Xue, P. Keskinocak et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.